This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aptose Biosciences (0UI8) Stock Overview

A clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. More details

0UI8 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Earnings have grown 7.7% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Negative shareholders equity

Shares are highly illiquid

Shareholders have been substantially diluted in the past year

+ 4 more risks

0UI8 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW477,249 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

477,249 investors already sharing narratives

View all narratives

Aptose Biosciences Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aptose Biosciences
Historical stock prices
Current Share Price	CA$5.16
52 Week High	CA$7.66
52 Week Low	CA$5.16
Beta	1.01
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-99.70%

Recent updates

Shareholder Returns

	0UI8	GB Biotechs	GB Market
7D	0%	0.3%	2.4%
1Y	n/a	-5.5%	19.0%

Return vs Industry: Insufficient data to determine how 0UI8 performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0UI8 performed against the UK Market.

Price Volatility

Is 0UI8's price volatile compared to industry and market?
0UI8 volatility
0UI8 Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	5.2%
10% most volatile stocks in GB Market	10.5%
10% least volatile stocks in GB Market	2.7%

Stable Share Price: 0UI8's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine 0UI8's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	13	William Rice	www.aptose.com

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.

Aptose Biosciences Inc. Fundamentals Summary

How do Aptose Biosciences's earnings and revenue compare to its market cap?
0UI8 fundamental statistics
Market cap	CA$3.57m
Earnings (TTM)	-CA$29.31m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is 0UI8 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0UI8 income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$21.33m
Earnings	-US$21.33m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-8.36
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-116.7%

How did 0UI8 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/20 02:51
End of Day Share Price	2025/03/24 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aptose Biosciences Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthew Venezia	Alliance Global Partners
Dylan Dupuis	B. Riley Securities, Inc.
John Newman	Canaccord Genuity

This company listing is no longer active

Aptose Biosciences (0UI8) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Aptose Biosciences Inc. Competitors

BSF Enterprise

ValiRx

Theracryf

Verici Dx

Price History & Performance

Recent News & Updates

Aptose Biosciences Inc. Files Form 15

Hanmi Pharm. Co., Ltd. (KOSE:A128940) completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc. (TSX:APS).

Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML

Aptose Biosciences Inc.'s Tuspetinib Triple Drug Therapy Featured At the 2025 ASH Annual Meeting

Hanmi Pharm. Co., Ltd. (KOSE:A128940) entered into a definitive arrangement agreement to acquire remaining 80.07% stake in Aptose Biosciences Inc. (TSX:APS) for CAD 4.9 million.

Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Recent updates

Aptose Biosciences Inc. Files Form 15

Hanmi Pharm. Co., Ltd. (KOSE:A128940) completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc. (TSX:APS).

Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML

Aptose Biosciences Inc.'s Tuspetinib Triple Drug Therapy Featured At the 2025 ASH Annual Meeting

Hanmi Pharm. Co., Ltd. (KOSE:A128940) entered into a definitive arrangement agreement to acquire remaining 80.07% stake in Aptose Biosciences Inc. (TSX:APS) for CAD 4.9 million.

Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Aptose Biosciences Inc. Enrollment Is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

The Nasdaq Stock Market to Delist the Common Shares of Aptose Biosciences

Aptose Biosciences Inc. Announces Resignation of Carol Ashe as Director, Effective June 16, 2025

Aptose Biosciences Inc. Presents Safety, Response, and MRD Clinical Data from Tuspetinib Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Announces Dosing of First Patient with 120 mg of Tuspetinib in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy After Dose Escalation Decision by Safety Review Committee

Aptose Biosciences Inc. Selects for Oral Presentation of Data from Tuscany Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed Aml At the 2025 Eha Congress

Aptose Provides Clinical Update for the Tuspetinib-Based Triple Drug Frontline Therapy in Newly Diagnosed AML Patients from the Phase 1/2 TUSCANY Trial

Nasdaq Determined to Delist Aptose Biosciences' Securities from The Nasdaq Stock Market, Effective on April 2, 2025

Aptose Biosciences Inc.(OTCPK:APTO.F) dropped from NASDAQ Composite Index

Aptose Biosciences Inc., Annual General Meeting, Jun 12, 2025

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Announces Positive Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort

Aptose Announces Reverse Share Split to Regain Compliance with Minimum Bid Price Requirement

Aptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 Tuscany Trial

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $1 million.

Aptose Biosciences Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Biosciences Inc. Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on Aml Cells When Combined with Venetoclax

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

Aptose Biosciences Inc. Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-Based Triplet Therapy

Aptose Biosciences Receives Staff Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Biosciences Inc. has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million.

Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023